Focusing on the Advances and Challenges of HER2-Targeted Therapy: Cutting-Edge Breakthroughs in Neoadjuvant Treatment for HER2-Positive Breast Cancer

HER2-positive breast cancer, characterized by overexpression of the human epidermal growth factor receptor 2 (HER2), accounts for approximately 15-20% of all breast cancers and is associated with aggressive tumor behavior and poor prognosis. Advances in HER2-targeted therapies, such as monoclonal an...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Anqi Shang MBBS, Yunjing Xiong MBBS, Min Li MBBS, Wanxin Tang MBBS, Keyu Wan MBBS, Zekang Deng MBBS, Xianxian Mao MBBS, Haizhu Chen MD, PhD
Formato:	Artigo
Idioma:	Inglês
Publicado em:	SAGE Publishing 2026-04-01
coleção:	Technology in Cancer Research & Treatment
Acesso em linha:	https://doi.org/10.1177/15330338261446455
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!